187.78
0.12%
-0.22
After Hours:
187.78
Penumbra Inc stock is currently priced at $187.78, with a 24-hour trading volume of 195.54K.
It has seen a -0.12% decreased in the last 24 hours and a -10.04% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $188.9 pivot point. If it approaches the $185.7 support level, significant changes may occur.
Previous Close:
$188.00
Open:
$187.47
24h Volume:
195.54K
Market Cap:
$7.28B
Revenue:
$1.10B
Net Income/Loss:
$93.39M
P/E Ratio:
182.31
EPS:
1.03
Net Cash Flow:
$105.36M
1W Performance:
-0.62%
1M Performance:
-10.04%
6M Performance:
-25.73%
1Y Performance:
-44.37%
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
510-748-3200
Address
1321 Harbor Bay Parkway, Alameda, CA
Penumbra Inc Stock (PEN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
Mar-29-23 | Downgrade | Needham | Buy → Hold |
Jan-30-23 | Initiated | Piper Sandler | Overweight |
Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
Oct-12-22 | Initiated | Jefferies | Buy |
Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
Sep-09-22 | Upgrade | Needham | Hold → Buy |
Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
Apr-19-22 | Initiated | Deutsche Bank | Buy |
Mar-08-22 | Initiated | Needham | Hold |
Sep-16-21 | Initiated | Truist | Buy |
Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
Oct-07-20 | Resumed | Canaccord Genuity | Buy |
Sep-29-20 | Initiated | BTIG Research | Buy |
Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
Mar-05-20 | Initiated | Citigroup | Buy |
Jun-13-19 | Reiterated | BofA/Merrill | Buy |
May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
May-21-19 | Initiated | William Blair | Outperform |
Oct-29-18 | Resumed | BofA/Merrill | Buy |
Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
Feb-21-18 | Initiated | William Blair | Outperform |
Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Zacks Investment Research
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term - Yahoo Finance UK
Yahoo Finance UK
Has Penumbra (PEN) Outpaced Other Medical Stocks This Year? - Yahoo New Zealand News
Yahoo New Zealand News
Braidwell LP Grows Stock Position in Penumbra, Inc. (NYSE:PEN) - MarketBeat
MarketBeat
Wall Street analysts' outlook for Penumbra Inc (PEN) – Sete News - SETE News
SETE News
KBC Group NV Invests $175000 in Penumbra, Inc. (NYSE:PEN) - Defense World
Defense World
Penumbra Inc Stock (PEN) Financials Data
Penumbra Inc (PEN) Revenue 2024
PEN reported a revenue (TTM) of $1.10 billion for the quarter ending March 31, 2024, a +23.87% rise year-over-year.
Penumbra Inc (PEN) Net Income 2024
PEN net income (TTM) was $93.39 million for the quarter ending March 31, 2024, a +1,341% increase year-over-year.
Penumbra Inc (PEN) Cash Flow 2024
PEN recorded a free cash flow (TTM) of $105.36 million for the quarter ending March 31, 2024, a +287.29% increase year-over-year.
Penumbra Inc (PEN) Earnings per Share 2024
PEN earnings per share (TTM) was $2.37 for the quarter ending March 31, 2024, a +1,381% growth year-over-year.
About Penumbra Inc
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Cap:
|
Volume (24h):